John Kilhefner

John Kilhefner

John Kilhefner is Senior Managing Editor of the Luke Lango franchise, which includes Hypergrowth Investing, Innovation Investor, Crypto Investor Network, and more.
Kilhefner has contributed to media such as Benzinga, The Hill, Tip Ranks, Unwinnable, The Arcade Review, Five Out of Ten magazine, and ZAM. He has appeared in U.S. News and World Report, Kotaku, USA Today, and Game Developer.
He now runs his own creative agency focused on tech and cybersecurity, called Skellator, LLC.
Learn more here

Recent Articles

Pandora Media Inc (P) Pops on Streaming Service

Pandora (P) stock is continuing Friday's huge move on news of an on-demand service and its potential for a merger.

Shopify Inc (SHOP) Stutters on Upgraded Price Target

Shopify (SHOP) is down nearly 1%, as investors grapple with just how much upside is really in SHOP stock. Here's what you need to know.

Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype

Cyclacel is up some 30% as a notable investor takes a sizable stake in CYCC stock. But does that mean you should heed the siren call?

VisionChina Media Inc (ADR) (VISN) Dives 7% on Stake Sale Update

VisionChina Media shareholders watched Monday losses cut into Friday's big bump in VISN amid new details of a stake sale to Ledman Optoelectronic.

Barnes & Noble, Inc. (BKS) Boots Its Ill-Fitting CEO

Barnes & Noble (BKS), while up huge in 2016, still kicked CEO Ronald Boire to the curb Tuesday, deeming him "not a good fit for the organization."

VIPS Stock: The Vipshop Holdings Ltd – ADR Growth Story Returns … For Now

VIPS posted phenomenal growth, but soft guidance is giving Vipshop Holdings investors pause. Here's what you need to know.

Dicks Sporting Goods Inc (DKS) Earnings Keep 2016’s Hot Run Alive

Dick's Sporting Goods (DKS) is extending its 2016 gains to nearly 70% on the heels of a second-quarter earnings beat. The future looks bright.

Synergy Pharmaceuticals Inc (SGYP): A Small-Cap Biotech With Momo On Its Side

Synergy Pharma (SGYP) stock continues barreling through the market with high volume as speculators hope for a buyout of this biotech name.

Best Buy Co Inc: BBY Stock Downgraded as 4K Prices Plunge

Best Buy (BBY) stock is bobbing in and out of the red Monday morning as investors react to Jefferies' bearish outlook on Best Buy TV sales.

Kura Oncology Inc: KURA Stock Delivers, But Don’t Trust It

Kura Oncology is seeing its biggest one-day gain yet, but that doesn't mean buy. Steer clear from the analysts on this one and look for a company with an actual product.